Monopar Therapeutics, Inc. (MNPR)
112.65
-1.73
(-1.51%)
USD |
NASDAQ |
Sep 09, 16:00
112.65
0.00 (0.00%)
After-Hours: 16:48
Monopar Therapeutics Total Liabilities (Quarterly) : 4.124M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 4.124M |
| March 31, 2026 | 2.589M |
| December 31, 2025 | 2.890M |
| September 30, 2025 | 2.639M |
| June 30, 2025 | 1.664M |
| March 31, 2025 | 1.492M |
| December 31, 2024 | 5.254M |
| September 30, 2024 | 1.123M |
| June 30, 2024 | 1.090M |
| March 31, 2024 | 1.435M |
| December 31, 2023 | 1.757M |
| September 30, 2023 | 1.982M |
| June 30, 2023 | 2.502M |
| March 31, 2023 | 2.888M |
| December 31, 2022 | 3.137M |
| September 30, 2022 | 1.935M |
| June 30, 2022 | 2.220M |
| March 31, 2022 | 1.100M |
| December 31, 2021 | 1.580M |
| September 30, 2021 | 1.240M |
| Date | Value |
|---|---|
| June 30, 2021 | 1.104M |
| March 31, 2021 | 0.8063M |
| December 31, 2020 | 1.177M |
| September 30, 2020 | 0.6645M |
| June 30, 2020 | 0.6481M |
| March 31, 2020 | 0.4435M |
| December 31, 2019 | 0.7242M |
| September 30, 2019 | 0.4837M |
| June 30, 2019 | 0.4683M |
| March 31, 2019 | 0.58M |
| December 31, 2018 | 0.3996M |
| September 30, 2018 | 0.3119M |
| June 30, 2018 | 0.3231M |
| March 31, 2018 | 0.2906M |
| December 31, 2017 | 0.3119M |
| September 30, 2017 | 0.3379M |
| June 30, 2017 | 0.2031M |
| March 31, 2017 | 0.3119M |
| December 31, 2016 | 0.0645M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Agenus, Inc. | 378.54M |
| Amgen, Inc. | 83.95B |
| Anika Therapeutics, Inc. | 46.19M |
| BioCryst Pharmaceuticals, Inc. | 1.012B |
| Imunon, Inc. | 10.80M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 134.98M |
| Shareholders Equity (Quarterly) | 130.86M |
| Debt to Equity Ratio | 0.0008 |
| Current Ratio | 33.56 |
| Net Debt Paydown Yield | 0.00% |